Publication Records

ŠTIKA, Jiří, Michaela PEŠOVÁ, Kateřina STAŇO KOZUBÍK, Magdalena SKALNÍKOVÁ, Lenka DOSTÁLOVÁ, Tomas LOJA, Lenka RADOVÁ, Veronika PALUŠOVÁ, Kamila RÉBLOVÁ, Zuzana VRZALOVÁ, Ivona BLAHÁKOVÁ, Jakub TRIZULJAK, Stjepan ULDRIJAN, Jan BLATNÝ, Michal ŠMÍDA, Šárka POSPÍŠILOVÁ and Michael DOUBEK. A novel thrombocytopenia-4-causing CYCS gene variant decreases caspase activity: Three-generation study. British journal of haematology. Hoboken: Wiley-Blackwell, 2024, 9 pp. ISSN 0007-1048. Available from: https://dx.doi.org/10.1111/bjh.19694.

BOBROWICZ, Malgorzata, Aleksandra KUSOWSKA, Marta KRAWCZYK, Andriy ZHYLKO, Christopher FORCADOS, Aleksander SLUSARCZYK, Joanna BARANKIEWICZ, Joanna DOMAGALA, Matylda KUBACZ, Michal ŠMÍDA, Lenka DOSTALOVÁ KOPEČNÁ, Katsiaryna MARHELAVA, Klaudyna FIDYT, Monika PEPEK, Iwona BARANOWSKA, Anna SZUMERA-CIECKIEWICZ, Else Marit INDERBERG, Sebastien WALCHLI, Monika GRANICA, Agnieszka GRACZYK-JARZYNKA, Martyna MAJCHRZAK, Marcin POREBA, Carina Lynn GEHLERT, Matthias PEIPP, Malgorzata FIRCZUK, Monika PROCHOREC-SOBIESZEK and Magdalena WINIARSKA. CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies. Oncoimmunology. Philadelphia: Taylor & Francis, 2024, vol. 13, No 1, p. 1-12. ISSN 2162-402X. Available from: https://dx.doi.org/10.1080/2162402X.2024.2362454.

PESCHELOVÁ, Helena, Veronika MANČÍKOVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Dominika ŠKRNOVÁ, Václav HEJRET and Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chornic lymphocytic leukemia. In CRISPR as a research tool in cancer and regenerative medicine, Stockholm, Švédsko. 2023.

PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Veronika MANČÍKOVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Dominika ŠKRNOVÁ, Václav HEJRET and Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia. In PhD and PostDoc RETREAT, Sněžné, Milovy. 2023.

ŠMÍDA, Michal. Efficacy of CD19-directed CAR-T cells against CLL and the possibilities for its further improvements. In XVIII. Myeloma VI. Cell Therapy Workshop – MCTW 2023. 2023.

LADUNGOVÁ, Adriana, Helena PESCHELOVÁ, Lenka DOSTÁLOVÁ, Yusuf LODHI, Narendra Varma GOTTUMUKKALA, Jiří MAYER and Michal ŠMÍDA. Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening. In The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood. 2023.

ŠTIKA, Jiří, Zuzana VRZALOVÁ, Kateřina STAŇO KOZUBÍK, Michaela PEŠOVÁ, Veronika PALUŠOVÁ, Lenka DOSTÁLOVÁ, Ivona BLAHÁKOVÁ, Lenka RADOVÁ, Michal ŠMÍDA, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Funkční efekt nově identifikované varianty v genu CYCS u rodiny s trombocytopenií typu 4. In 23. Pražské hematologické dny, Praha. 2023.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Helena PESCHELOVÁ, Tomáš LOJA and Michal ŠMÍDA. Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. In CRISPR as a research tool in cancer and regenerative medicine, Stockholm, Švédsko. 2023.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Helena PESCHELOVÁ, Tomáš LOJA and Michal ŠMÍDA. Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation in rituximab-resistant cells. In PhD and PostDoc RETREAT, Sněžné, Milovy. 2023.

GOTTUMUKKALA, Narendra Varma, Aneta LEDEREROVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Yusuf LODHI and Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity py preventing CD19 antigen escape in relapsed models. In EHA Meeting – 5th European CAR T-cell Meeting, Rotterdam, Nizozemsko. 2023.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Helena PESCHELOVÁ, Tomáš LOJA and Michal ŠMÍDA. Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genomewide CRISPR screening. In XX. International Workshop on CLL (iwCLL 2023), Boston, USA. 2023.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN and Michal ŠMÍDA. Identificationof novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In 23. Pražské hematologické dny, Praha. 2023.

ŠTIKA, Jiří, Zuzana VRZALOVÁ, Kateřina STAŇO KOZUBÍK, Michaela PEŠOVÁ, Veronika PALUŠOVÁ, Lenka DOSTÁLOVÁ, Ivona BLAHÁKOVÁ, Lenka RADOVÁ, Michal ŠMÍDA, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Nově identifikovaná varianta v genu CYCS u rodiny s trombocytopenií typu 4 a její funkční dopad. In 25. celostátní konference DNA diagnostiky. 2023.

ŠTIKA, Jiří, Zuzana VRZALOVÁ, Kateřina STAŇO KOZUBÍK, Michaela PEŠOVÁ, Veronika PALUŠOVÁ, Lenka DOSTÁLOVÁ, Ivona BLAHÁKOVÁ, Lenka RADOVÁ, Petra SEDLÁKOVÁ, Radim SONNEK, Michal ŠMÍDA, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Varianta v genu CYCS způsobující trombocytopenii 4 zvyšuje kaspázovou aktivitu. (A variant in the CYCS gene causing thrombocytopenia 4 increases caspase activity.). In 56. Výroční cytogenomická konference, Ostrava. 2023.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN and Michal ŠMÍDA. . Drug repurposing for venetoclax-resistant acute myeloid leukemia. In PhD retreat 2022, Telč. 2022.

SKALNÍKOVÁ, Magdalena, Kateřina STAŇO KOZUBÍK, Jakub TRIZULJAK, Zuzana VRZALOVÁ, Lenka RADOVÁ, Kamila RÉBLOVÁ, Radka HOLBOVÁ, Terézia KURUCOVÁ, Hana SVOZILOVÁ, Jiří ŠTIKA, Ivona BLAHÁKOVÁ, Barbara DVOŘÁČKOVÁ, Marie PRUDKOVÁ, Olga STEHLÍKOVÁ, Michal ŠMÍDA, Leoš KŘEN, Petr SMEJKAL, Šárka POSPÍŠILOVÁ and Michael DOUBEK. A GP1BA Variant in a Czech Family with Monoallelic Bernard-Soulier Syndrome. International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2022, vol. 23, No 2, p. 1-13. ISSN 1422-0067. Available from: https://dx.doi.org/10.3390/ijms23020885.

DOSTÁLOVÁ, Lenka, Adriana LADUNGOVÁ, Dominika ŠKRNOVÁ, Narendra Varma GOTTUMUKKALA, Yusuf LODHI and Michal ŠMÍDA. Combined drug and CRISPR/CAS9 screening reveals specific targets for SF3B1- and NOTCH1- mutated CLL cells. In EHA 2022 in HemaSphere 2022; 6(S3): 1012-1013. 2022.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Helena PESCHELOVÁ, Václav HEJRET and Michal ŠMÍDA. CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. In Annual PhD conference Biomedical sciences, Brno. 2022.

DOSTÁLOVÁ, LEDEREROVÁ, PESCHLOVÁ and Michal ŠMÍDA. CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. In PhD retreat 2022, Telč. 2022.

LODHI, Yusuf, Adriana LADUNGOVÁ, Daniel BUŠA, Helena PESCHELOVÁ, Martin ČULEN and Michal ŠMÍDA. Genome-wide Screening Optimizations and High-throughput Compound Screening to Identify Novel Treatment Options in Venetoclax-resistant AML. In Annual PhD conference Biomedical sciences, Brno. 2022.

GOTTUMUKKALA, Narendra Varma, Veronika MANČÍKOVÁ, Aneta LEDEREROVÁ, Veronika KOZLOVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Yusuf LODHI, Jan VERNER and Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models. In XVII. Myeloma and Cell Therapy Workshop, Ostrava. 2022.

GOTTUMUKKALA, Narendra Varma, Veronika MANČÍKOVÁ, Aneta LEDEREROVÁ, Veronika KOZLOVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Yusuf LODHI, Jan VERNER and Michal ŠMÍDA. Chasing the epigenetic landscape to enhance CAR-T cell activity by preventing CD19 antigen escape in relapsed models. In Annual PhD conference Biomedical sciences, Brno. 2022.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN and Michal ŠMÍDA. Identification of novel therapeutic options for venetoclax-resistant AML cells through drug repurposing. In EHA 2022 in HemaSphere 2022; 6(S3): 626-627. 2022.

DAVE, Zankruti, Olga VONDÁLOVÁ BLANÁŘOVÁ, Štěpán ČADA, Pavlína JANOVSKÁ, Nikodém ZEZULA, Martin BĚHAL, Kateřina HANÁKOVÁ, Sri Ranjani GANJI, Pavel KREJČÍ, Kristína GÖMÖRYOVÁ, Helena PESCHELOVÁ, Michal ŠMÍDA, Zbyněk ZDRÁHAL, Šárka PAVLOVÁ, Jana KOTAŠKOVÁ, Šárka POSPÍŠILOVÁ and Vítězslav BRYJA. Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells. Frontiers in Cell and Developmental Biology. Frontiers Media SA, 2022, vol. 10, February 2022, p. 1-11. ISSN 2296-634X. Available from: https://dx.doi.org/10.3389/fcell.2022.838871.

LADUNGOVÁ, Adriana, Daniel BUŠA, Helena PESCHELOVÁ, Yusuf LODHI, Martin ČULEN and Michal ŠMÍDA. Prediction of novel treatment options for CLL and AML cells based on drug repurposing. In CEITEC PhD Conference, Brno. 2022.

LADUNGOVÁ, Adriana, Daniel BUŠA, Yusuf LODHI, Jan HÝL, Martin ČULEN and Michal ŠMÍDA. Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing. In Functional Precision Medicine for Blood Cancer Workshop and Symposium, Helsinki, Finland. 2022.

ŠMÍDA, Michal. The use of functional genomics for advancing monoclonal antibody therapy of chronic lymphocytic leukemia. In Alliance4Life thematic miniconference, Smolenice, Slovakia. 2022.

ŠMÍDA, Michal. CD19 hypermethylation as an escape to CART-19. In 3rd European CAR-T cell meeting. 2021.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Veronika KOZLOVÁ, Helena PESCHELOVÁ, Adriana LADUNGOVÁ, Veronika MANČÍKOVÁ and Michal ŠMÍDA. CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy. In XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). 2021.

ŠMÍDA, Michal. CD19 promotor hypermethylation results in CD19 antigen-negative relapse to CAR-T cells. In XVI. Myeloma and IV. Cell Therapy Workshop. 2021.

MANČÍKOVÁ, Veronika and Michal ŠMÍDA. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. Basel: Multidisciplinary Digital Publishing Institute, 2021, vol. 22, No 11, p. 5536-5546. ISSN 1422-0067. Available from: https://dx.doi.org/10.3390/ijms22115536.

LADUNGOVÁ, Adriana, Helena PESCHELOVÁ, Veronika KOZLOVÁ and Michal ŠMÍDA. Drug repositioning in genetically defined CLL cases reveals a potentional novel therapeutic use for approved drugs. In II. Český hematologický a transfuziologický sjezd v Transfuze a Hematologie Dnes (2021). 2021.

STAŇO KOZUBÍK, Kateřina, Lenka RADOVÁ, Kamila RÉBLOVÁ, Michal ŠMÍDA, Marketa KUBRICANOVA ZALIOVA, Jiří BALOUN, Michaela PEŠOVÁ, Zuzana VRZALOVÁ, František FOLBER, Soňa MEJSTŘÍKOVÁ, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Functional analysis of germlineETV6 W380Rmutation causing inherited thrombocytopenia and secondary acute lymphoblastic leukemia or essential thrombocythemia. Platelets. PHILADELPHIA: TAYLOR & FRANCIS INC, 2021, vol. 32, No 6, p. 838-841. ISSN 0953-7104. Available from: https://dx.doi.org/10.1080/09537104.2020.1802416.

LEDEREROVÁ, Aneta, Lenka DOSTÁLOVÁ, Veronika KOZLOVÁ, Helena PESCHELOVÁ, Adriana LADUNGOVÁ, Martin ČULEN, Tomáš LOJA, Jan VERNER, Šárka POSPÍŠILOVÁ, Michal ŠMÍDA and Veronika MANČÍKOVÁ. Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro. Journal for ImmunoTherapy of Cancer. Switzerland: Springer International Publishing AG, 2021, vol. 9, No 8, p. 1-8. ISSN 2051-1426. Available from: https://dx.doi.org/10.1136/jitc-2021-002352.

ŠMÍDA, Michal. Identification of biomarkers and escape mechanisms for CAR-T cell therapy in chronic lymphocytic leukemia. In Visegrad meeting. 2021.

DOSTÁLOVÁ, Lenka, Aneta LEDEREROVÁ, Veronika KOZLOVÁ, Helena PESCHELOVÁ, Adriana LADUNGOVÁ, Tomáš LOJA, Jan VERNER, Šárka POSPÍŠILOVÁ, Veronika MANČÍKOVÁ and Michal ŠMÍDA. In vivo antigen-negative escape to CART-19 caused by CD19 promotor hypermethylation. In II. Český hematologický a transfuziologický sjezd v Transfuze a Hematologie Dnes (2021). 2021.

STAŇO KOZUBÍK, Kateřina, Zuzana VRZALOVÁ, Jakub TRIZULJAK, Magdalena SKALNÍKOVÁ, Lenka RADOVÁ, Ivona BLAHÁKOVÁ, Jiří ŠTIKA, Veronika BERGEROVÁ, Michal ŠMÍDA, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Kongenitální neutropenie u dětí a dospělých (Congenital neutropenia in children and adults). Transfúze a hematologie dnes. Mladá fronta a.s., 2021, vol. 27, No 4, p. 297-303. ISSN 1213-5763. Available from: https://dx.doi.org/10.48095/cctahd2021297.

FAJTLOVÁ, Šárka, Ivan REKTOR, Michal ŠMÍDA and Štěpánka VAŇÁČOVÁ. Open Week. 2021.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Adriana LADUNGOVÁ, Helena PESCHELOVÁ, Pavlína JANOVSKÁ, A. SLUSARCZYK, J. DOMAGALA, Pavel KOPČIL, Viera VAKULOVÁ, Jan OPPELT, Vítězslav BRYJA, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. Plos one. San Francisco: Public Library Science, 2020, vol. 15, No 3, p. 0229170-229189. ISSN 1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0229170.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Veronika MANČÍKOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Combination of epigenetic drug screen and CRISPR knockout screen as an unbiased approach to reveal possible CD20 therapy improvement. In XXth Interdisciplinary meeting of young researchs and students in the field of chemistry, biochemistry, molecular biology and biomaterials in Chemické listy. 2020.

LEDEREROVÁ, Aneta, Veronika KOZLOVÁ, Veronika MANČÍKOVÁ, Helena PESCHELOVÁ, J. PERSSON, B. SCHMIERER, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Combination of epigenetic drug screen and CRISPR knockout screen revealed involvement of aurora kinases and Cullin 3 in CD20 regulation. In 25th Congress of European Hematology Association, Amsterdam, Nizozemsko, in HemaSphere. 2020.

PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Veronika MANČÍKOVÁ, Adriana LADUNGOVÁ, Václav HEJRET and Michal ŠMÍDA. CRISPR/CAS9 technology: a useful tool in the study of chronic lymphocytic leukemia. In XXth Interdisciplinary meeting of young researchs and students in the field of chemistry, biochemistry, molecular biology and biomaterials in Chemické listy. 2020. ISSN 2336-7202.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Veronika MANČÍKOVÁ, Jiří MAYER, Šárka POSPÍŠILOVÁ, Michael DOUBEK and Michal ŠMÍDA. Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells. In XVIII. International Workshop on CLL, Edinburgh, Skotsko. 2020. ISSN 1042-8194.

PESCHELOVÁ, Helena, Lenka DOSTÁLOVÁ, Veronika KOZLOVÁ, Aneta LEDEREROVÁ, Václav HEJRET and Michal ŠMÍDA. Genome-wide CRISPR/Cas9 screening reveals novel target genes, whose inactivation is able to upregulate surface expression of immunotherapy target CD20. In 25th Congress of European Hematology Association, Amsterdam, Nizozemsko, in HemaSphere. 2020.

MANČÍKOVÁ, Veronika, Veronika KOZLOVÁ, Helena PESCHELOVÁ, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Impact of genetics on the performance of anti-CD 19 chimeric antigen receptor T cells in chronic lymphocytic leukemia. In 2nd European CAT T Cell Meeting. 2020.

MANČÍKOVÁ, Veronika, Helena PESCHELOVÁ, Veronika KOZLOVÁ, Aneta LEDEREROVÁ, Adriana LADUNGOVÁ, Jan VERNER, Tomáš LOJA, František FOLBER, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia. Journal for ImmunoTherapy of Cancer. Switzerland: Springer International Publishing AG, 2020, vol. 8, No 1, p. 000471-481. ISSN 2051-1426. Available from: https://dx.doi.org/10.1136/jitc-2019-000471.

PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Veronika MANČÍKOVÁ, Adriana LADUNGOVÁ, Václav HEJRET and Michal ŠMÍDA. The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia. In CEITEC PhD Conference. 2020.

PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Václav HEJRET and Michal ŠMÍDA. CRISPR/Cas9 gene editing and functional screening in chronic lymphocytic leukemia. In Joint retreat 2019, Kouty u Ledče nad Sázavou. 2019. ISBN 978-80-210-9300-3.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Epigenetic drug screen of a CD20-low expressing cell line revealed an unexpected role of Aurora kinase inhibitors in CD20 expression. In 6th Prague-Weizmann Summer School Advances in Drug Discovery, Praha. 2019.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Epigenetic drug screen of CD20-low expressing cell line revealed possible treatment target. In Joint retreat 2019, Kouty u Ledče nad Sázavou. 2019.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Veronika MANČÍKOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Epigenetic drug screen on CD20 immunotherapy resistant cells revealed possible role of Aurora kinase inhibitors in CD20 expression regulation. In 5th Annual International Conference New Concepts in Lymphoid Malignancies, Estoril, Portugalsko. 2019.

MANČÍKOVÁ, Veronika, Veronika KOZLOVÁ, Helena PESCHELOVÁ, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Performance of α-CD19 Chimeric Antigen Receptor T cells in genetically defined classes of Chronic Lymphocytic Leukemia. In 5th Annual International Conference New Concepts in Lymphoid Malignancies, Estoril, Portugalsko. 2019.

ŠMÍDA, Michal. Revoluce v imunoterapii nádorů: CAR-T lymfocyty (Revolution in tumor immunotherapy: CAR-T lymphocytes). In XXIII. Biologické dny 2019 – moderní trendy biomedicínského výzkumu, Brno. 2019.

PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Václav HEJRET and Michal ŠMÍDA. The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia. In Biomania, Brno. 2019.

ŠMÍDA, Michal. ASH 2017 – novinky laboratorní. In X. Plenární zasedání ČS CLL, Praha. 2018.

PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. CRISPR/Cas9-mediated gene knockout of TP53 and ATM in HG3 cell line: models for chronic lymphocytic leukemia. In CEITEC PHD and POSTDOC RETREAT. 2018.

PEŠOVÁ, Michaela, Kateřina STAŇO KOZUBÍK, Karol PÁL, Michal ŠMÍDA, Jiří BALOUN, Lenka RADOVÁ, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Dědičné trombocytopenie (Inherited thrombocytopenias). Transfuze a Hematologie Dnes. Praha: Ceska Lekarska Spolecnost J.E. Purkyne/Czech Medical Association, 2018, vol. 24, No 1, p. 14-26, 14 pp. ISSN 1213-5763.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Epigenetic drug screen of rituximab resistant cell line revealed possible treatment targets. In Czech Chemical Society Symposium Series in Chemické Listy. 2018.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Epigenetic drug screen on resistant CLL cells reveals Aurora kinase inhibitors as enhancers of CD20 expression and sensitizers to treatment with CD20 monoclonal antibodies. In 60th ASH Annual meeting, San Diego, USA in Blood 2018. 2018.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Epigenetic drug screen on rituximab-resistant cells revealed in unexpected role of Aurora kinase inhibitors in CD20 expression. 2018.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Epigenetický screening buněk rezistentních k rituximabu odhalil možnou roli inhibitorů Aurora kináz v regulaci exprese CD20 (Epigenetic screening of rituximab-resistant cells revealed the potential role of Aurora kinase inhibitors in regulating CD20 expression). In I. Český hematologický a transfuziologický sjezd, Praha in Transfuze a hematologie dnes. 2018.

ŠMÍDA, Michal. Functional genomics to predict novel targets for personalized therapy of B-cell malignancies. In CEITEC Principal Investigator Seminar. 2018.

KOZLOVÁ, Veronika. Functional genomics to reveal novel opportunities for CD20 antibody therapy of B-cell malignancies. In EU-LIFE meeting on precision medicine 2018, Paříž, Francie. 2018.

KOZLOVÁ, Veronika. Functional genomics to reveal novel opportunities for CD20 antibody therapy of B-cell malignancies. In EU-LIFE scientific meeting, Paříž. 2018.

ŠMÍDA, Michal, Jiří MAYER and Veronika MANČÍKOVÁ. T lymfocyty s chimerickým receptorem (CAR): revoluce v imunoterapii nádorů. In XIII. Brněnské hematologické dny/Novinky v hematologii, Brno. 2018.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Unexpected role of Aurora kinase inhibitors in CD20 expression. In CEITEC PHD and POSTDOC RETREAT 2018. 2018.

KOČKOVÁ, Helena, Karla PLEVOVÁ, Jitka MALČÍKOVÁ, Jana KOTAŠKOVÁ, Vojtěch BYSTRÝ, Veronika MANČÍKOVÁ, Martin TRBUŠEK, Michaela HLOŽKOVÁ, Yvona BRYCHTOVÁ, Michael DOUBEK and Šárka POSPÍŠILOVÁ. B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia. In CEITEC PHD RETREAT II. 2017.

OLBERTOVÁ, Helena, Karla PLEVOVÁ, Jitka MALČÍKOVÁ, Jana KOTAŠKOVÁ, Vojtěch BYSTRÝ, Veronika MANČÍKOVÁ, Tomáš LOJA, Martin TRBUŠEK, Michaela ŠPUNAROVÁ, Yvona BRYCHTOVÁ, Michael DOUBEK and Šárka POSPÍŠILOVÁ. B cell receptor signaling actvity is associated with genomic defects in chronic lymphocytic leukemia. In Nucleic Acids and Immunity. 2017.

LEDEREROVÁ, Aneta, Veronika KOZLOVÁ, Viera VAKULOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. B cells resistant to CD20 monoclonal antibodies display specific alterations in gene expression profile. In 22nd congress of EHA, Madrid, Španělsko, červen 2017 in Haematologica (2017). 2017.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Viera VAKULOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. CD20 knockout cell lines obtained using CRISPR/Cas9 have no significant defect in BCR signaling in B-lymphoid malignancies. In CEITEC PHD RETREAT II, Telč. 2017.

LEDEREROVÁ, Aneta, Veronika KOZLOVÁ, Viera VAKULOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Cellular mechanisms regulating CD20 as a target of monoclonal antibody therapy in B-lymphoid malignancies. In EMBO Practical Course: Current Methods in Cell Biology, Heidelberg, Německo. 2017.

PEŠOVÁ, Michaela, Kateřina STAŇO KOZUBÍK, Karol PÁL, Lenka RADOVÁ, Michal ŠMÍDA, Jiří BALOUN, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Exomové sekvenování v diagnostice dědičných trombocytopenií. In Brněnský genetický den, Brno. 2017.

ŠMÍDA, Michal. Mechanisms of resistance to monoclonal antibodies in CLL. In Scientific and Clinical Preceptorship: Chronic Lymphocytic Leukemia, Brno. 2017.

DE LA CRUZ, F.F., Michal ŠMÍDA and M. NIJMAN. MEK inhibitors block growth of Ataxia Telangiectasia Mutated (ATM) mutant lung tumors. In AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer. 2017. ISSN 1535-7163. Available from: https://dx.doi.org/10.1158/1538-8514.SYNTHLETH-PR14.

PEŠOVÁ, Michaela, Kateřina STAŇO KOZUBÍK, Karol PÁL, Michal ŠMÍDA, Jiří BALOUN, Zuzana VRZALOVÁ, Lenka RADOVÁ, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Význam a využití NGS v diagnostice dědičných trombocytopenií. (Importance and use of NGS in the diagnosis of hereditary thrombocytopenia). In Pražský hematologický den, Praha. 2017.

ŠMÍDA, Michal, Veronika KOZLOVÁ, Viera VAKULOVÁ, Aneta LEDEREROVÁ, Michael DOUBEK, Jiří MAYER and Šárka POSPÍŠILOVÁ. Cellular mechanisms regulating CD20 as a target of monoclonal antibody therapy in B-lymphoid malignancies. In Blood (2016); s. 3968. (58th ASH Annual Meeting and Exposition, San Diego, USA, prosinec 2016). 2016.

KOZLOVÁ, Veronika, Viera VAKULOVÁ, Aneta LEDEREROVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Cellular mechanisms regulating CD20 as a target of monoclonal antibody therapy in B-lymphoid malignancies. In 2nd International Conference on New Concepts in B-Cell Malignancies, Estoril, Portugalsko, září 2016. 2016.

ŠMÍDA, Michal, Ferran Fece DE LA CRUZ, Claudia KERZENDORFER, Iris Z. URAS, Barbara MAIR, Abdelghani MAZOUZI, Tereza SUCHANKOVA, Tomasz KONOPKA, Amanda M. KATZ, Keren PAZ, Katalin NAGY-BOJARSZKY, Markus K. MUELLNER, Zsuzsanna BAGO-HORVATH, Eric B. HAURA, Joanna I. LOIZOU and Sebastian M. B. NIJMAN. MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. Nature Communications. London: Nature Publishing Group, 2016, vol. 7, December, p. nestránkováno, 13 pp. ISSN 2041-1723. Available from: https://dx.doi.org/10.1038/ncomms13701.

ŠMÍDA, Michal. Nové technologie v medicíně: CAR T lymfocyty – převratná metoda v léčbě hematologických malignit. In Novinky v hematologii, Brno. 2016.

LEDEREROVÁ, Aneta, Veronika KOZLOVÁ, Viera VAKULOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Příprava linií rezistentních k působení anti-CD20 monoklonálních protilátek a analýza signálních drah u B-lymfoidních malignit. In Pražský hematologický den, říjen 2016. 2016.

KOZLOVÁ, Veronika, Aneta LEDEREROVÁ, Viera VAKULOVÁ, Michael DOUBEK, Jiří MAYER, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Vyřazení genu CD20 pomocí CRISPR/Cas9 knockoutu nezpůsobí žádný defekt v BCR signalizaci u B-lymfoidních malignit. In Pražský hematologický den, říjen 2016. 2016.

STAŇO KOZUBÍK, Kateřina, Karol PÁL, Lenka RADOVÁ, Michal ŠMÍDA, Kamila RÉBLOVÁ, Karla PLEVOVÁ, Šárka POSPÍŠILOVÁ and Michael DOUBEK. Využití celoexomového sekvenování. In XXX. Olomoucké hematologické dny. 2016.

ŠMÍDA, Michal. Chimérický antigenní receptor T lymfocytů- genová terapie budoucnosti u nádorových onemocnění? (Chimeric Antigen Receptor T-cells- Gene Therapy of the Future for Malignant Diseases?). Klinická onkologie: časopis České a Slovenské onkologické společnosti. Brno: C̆eská onkologická spolec̆nost Slovenská onkologicka spolecnost, 2015, vol. 28, No 4, p. "4S44"- "4S47", 4 pp. ISSN 0862-495X. Available from: https://dx.doi.org/10.14735/amko20154S44.

DOUBEK, Michael and Michal ŠMÍDA. Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? Expert Review of Hematology. ABINGDON: TAYLOR & FRANCIS LTD, 2015, vol. 8, No 6, p. 743-764. ISSN 1747-4086. Available from: https://dx.doi.org/10.1586/17474086.2015.1079123.

VAKULOVÁ, Viera, Michael DOUBEK, Šárka POSPÍŠILOVÁ and Michal ŠMÍDA. Vplyv terapie monoklonálnými protilátkami u chronickej lymfocytovej leukémie a B-lymfómov na expresiu antigénu CD20. In XVII. Slovensko-český hematologický a transfuziologický zjazd, Bratislava, Slovensko. 2015.